Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the disease’s progression. RAAS inhibitors are the standard of care for CKD, but newer agents from the SGLT-2 inhibitor and MRA classes could transform the treatment algorithm. In 2021, AstraZeneca’s Farxiga (dapagliflozin) became the first SGLT-2 inhibitor to demonstrate a renoprotective effect in a dedicated CKD outcomes trial and receive approval from the FDA for the treatment of CKD irrespective of the presence of diabetes. Also in 2021, Bayer’s MRA Kerendia (finerenone) received approval for CKD after it demonstrated renoprotective and cardioprotective benefits in type 2 diabetes patients with CKD in the FIDELIO-DKD and FIGARO-DKD trials. In 2022, Eli Lilly’s Jardiance (empagliflozin) demonstrated renoprotective benefits in the EMPA-KIDNEY trial.
Markets covered: United States.
Key companies: AstraZeneca, Eli Lilly, Boehringer Ingelheim.
Key drugs: Jardiance, Farxiga, Invokana, Kerendia.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.